Literature DB >> 21764887

Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.

Stefan Glück1, Carlos L Arteaga, C Kent Osborne.   

Abstract

The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others. ©2011 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21764887     DOI： 10.1158/1078-0432.CCR-10-2051

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  15 in total

1.  First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.

Authors:  Debu Tripathy; Peter A Kaufman; Adam M Brufsky; Musa Mayer; Marianne Ulcickas Yood; Bongin Yoo; Cheng Quah; Denise Yardley; Hope S Rugo
Journal:  Oncologist       Date:  2013-05-07

Review 2.  Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.

Authors:  Virginia G Kaklamani; William J Gradishar
Journal:  Oncologist       Date:  2017-03-17

3.  Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.

Authors:  Justin D Lathia; Ofer Reizes; Praveena S Thiagarajan; Masahiro Hitomi; James S Hale; Alvaro G Alvarado; Balint Otvos; Maksim Sinyuk; Kevin Stoltz; Andrew Wiechert; Erin Mulkearns-Hubert; Awad Jarrar; Qiao Zheng; Dustin Thomas; Thomas Egelhoff; Jeremy N Rich; Huiping Liu
Journal:  Stem Cells       Date:  2015-05-15       Impact factor: 6.277

4.  Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report.

Authors:  Jian Wang; Chunxiao Sun; Xiang Huang; Jinrong Qiu; Yongmei Yin
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

5.  Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.

Authors:  Senthilkumar Damodaran; Erin M Olson
Journal:  Hosp Pract (1995)       Date:  2012-10

6.  N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

Authors:  Jennifer A Crozier; Pooja P Advani; Betsy LaPlant; Timothy Hobday; Anthony J Jaslowski; Alvaro Moreno-Aspitia; Edith A Perez
Journal:  Clin Breast Cancer       Date:  2015-08-19       Impact factor: 3.225

7.  An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.

Authors:  Francisco J Esteva; Sandra X Franco; Maura K Hagan; Abenaa M Brewster; Robert A Somer; Will Williams; Allison M Florance; Simon Turner; Steven Stein; Alejandra Perez
Journal:  Oncologist       Date:  2013-05-22

8.  HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Authors:  Olivier Humbert; Alexandre Cochet; Jean-Marc Riedinger; Alina Berriolo-Riedinger; Laurent Arnould; Bruno Coudert; Isabelle Desmoulins; Michel Toubeau; Inna Dygai-Cochet; Séverine Guiu; Charles Coutant; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-20       Impact factor: 9.236

9.  Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.

Authors:  Claudia Marcela Diaz; Alberto Chiappori; Luigi Aurisicchio; Ansuman Bagchi; Jason Clark; Sheri Dubey; Arthur Fridman; Jesus C Fabregas; John Marshall; Elisa Scarselli; Nicola La Monica; Gennaro Ciliberto; Alberto J Montero
Journal:  J Transl Med       Date:  2013-03-08       Impact factor: 5.531

10.  Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.

Authors:  Eugene R Ahn; Emilie Wang; Stefan Glück
Journal:  Breast Cancer (Auckl)       Date:  2012-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.